Gastric Cancer Pipeline Insight, Clinical Trial Analysis and NDA Approvals | 230+ Companies and 230+ Drugs

Gastric Cancer Pipeline Insight, Clinical Trial Analysis and NDA Approvals | 230+ Companies and 230+ Drugs

DelveInsight’s, “Gastric Cancer Pipeline Insight 2023” report provides comprehensive insights about 230+ companies and 230+ pipeline drugs in Gastric Cancer pipeline landscape. It covers the Gastric Cancer pipeline drug profiles, including Gastric Cancer clinical trial and nonclinical stage products. It also covers the Gastric Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Gastric Cancer Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Gastric Cancer NDA approvals (if any), and product development activities comprising the technology, Gastric Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.

 

Key takeaways from the Gastric Cancer Pipeline Report

  • Over 230+ Gastric Cancer companies are evaluating 230+ Gastric Cancer therapies in various stages of development, and their anticipated acceptance in the Gastric Cancer market would significantly increase market revenue.
  • The leading Gastric Cancer Companies are working to develop drug candidates to improve Gastric Cancer treatment landscape include Hutchison Medipharma Limited, EMD Serono, Sumitomo Pharma, Jiangsu HengRui Medicine Co., Ltd., LintonPharm Co.,Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Eli Lilly and Company, Janssen Pharmaceutical K.K., Hoffmann-La Roche, Novartis, Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Merck Sharp & Dohme LLC, Amgen, Hanmi Pharmaceutical, and others.
  • Promising Gastric Cancer Pipeline therapies in various stages of the development include Avelumab, BBI608, Camrelizumab, Catumaxomab, RAPA-201, SHR-1210, Amivantamab, Atezolizumab, Bevacizumab, Cabozantinib, Cinrebafusp alfa, Crizotinib, DKN-01, DP303c, Eflornithine, EP0057, Epacadostat, FLX475, Futibatinib, GEN-001, HLX07, HLX22, Infigratinib, KH903, Lenvatinib, Masitinib, MAX-40279, MRG002, MRG003, Niraparib, Savolitinib, Minnelide, SHR-1701, Margetuximab, Bemarituzumab, Evorpacept, Lenvatinib, CDK-004, TPX-0022,  TCRx_T Cells,  IN10018, IMU-131, SOT102, CT041, AB011, Zanidatamab, NC410,  PT 886, PRS-343, Oraxol, CA-4948,  Q702,  ACE1702, SI-B001, TT-4, LUM015,  LB 1908, CUE-102,  TORL-2-307-MAB,  OBI-833/OBI-821,  ASP2138, NC410, SO-C101, HC-5404-FU, CPL304110,  LNS8801, RGX-202-01, A166, GZ17-6.02, HMPL-453,  CCT303-406, VMD-928,  ITI 4000, PAb 001, and others.
  • The Gastric Cancer Companies and academics are working to assess challenges and seek opportunities that could influence Gastric Cancer R&D. The Gastric Cancer pipeline therapies under development are focused on novel approaches to treat/improve Gastric Cancer.
  • Gastric Cancer pipeline report encloses its detailed analysis of various drugs in different stages of Gastric Cancer clinical trial development, including phase II, I, preclinical and Discovery.

 

To explore more information on the latest breakthroughs in the Gastric Cancer treatment landscape of the report, click here @ Gastric Cancer Pipeline Outlook

 

Recent Developmental Activities in the Gastric Cancer Treatment Landscape

  • In December 2022, Daiichi Sankyo and AstraZeneca’s ENHERTU (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with advanced HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
  • In December 2022, RemeGen Co., Ltd. announced on December 7, 2022, that its latest antibody-drug conjugate (ADC), RC118 for injection, has been granted two orphan drug designations (ODD) by the United States Food and Drug Administration (FDA) for gastric cancer (including gastroesophageal junction cancer) and pancreatic cancer. This marks the Company’s fourth, having previously been twice granted ODD for Disitamab Vedotin (RC48) and Telitacicept (RC18) earlier this year.
  • In December 2022, Zhejiang Doer Biologics Co., Ltd. announced that it has entered into a clinical trial collaboration agreement with MSD (Merck & Co., Inc.,  Rahway, NJ, USA), to investigate Doer Bio’s anti-Claudin18.2 antibody DR30303, in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with Gastric or Gastroesophageal Junction Cancer. Under this agreement, Doer Bio will conduct a clinical study based on a mutually- agreed and finalized protocol to evaluate the safety and efficacy of DR30303 in combination with KEYTRUDA® in patients with Claudin18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GC/GEJ) cancer.
  • In November 2022, Triumvira Immunologics announced preclinical data for its investigational TAC-T cell therapies CLDN18.2-TAC T and GUCY2C-TAC T, and data on HER2-specific TAC-T products. Data was shared in three posters at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting being held virtually and in-person in Boston.Triumvira announced updated data on its novel T cell antigen coupler (TAC)-T cell candidate targeting Claudin 18.2 (CLDN18.2) for the treatment of gastric cancer. The data continue to demonstrate that CLDN18.2-TAC T effectively eliminates CLDN18.2-expressing gastric cancer cells in vitro and in vivo. The study also demonstrated that the activation of CLDN18.2-TAC T cells was specific to target cells that expressed CLDN18.2. In vitro data show strong and persistent anti-tumor activity and in vivo treatment led to complete and sustained tumor clearance with no signs of toxicity.
  • In September 2022, Nuvectis Pharma, Inc. announced positive data for NXP800 in a preclinical xenograft model of ARID1a-mutated gastric carcinoma.Mice in each group were treated with either vehicle or NXP800, and tumor volumes were measured over 28 days. Treatment with NX800 resulted in tumor regression and substantial tumor growth inhibition versus the control.
  • In March 2022, Imugene (ASX: IMU) announced a new clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to evaluate the safety and efficacy of Imugene’s HER-Vaxx, B-cell activating immunotherapy, in combination with MSD’s anti-PD-1 therapy, pembrolizumab (KEYTRUDA®), in patients with HER-2 positive gastric cancer.

 

Gastric Cancer Overview

Stomach cancer is cancer that starts anywhere inside the stomach or the stomach wall. It’s also called gastric cancer. Stomach cancer is more common in older people. Around 50 out of 100 cases (around 50%) occur in people aged 75 or over. It is more common in men than women. Many stomach cancers are linked to lifestyle or environmental factors, including diet. Stomach cancer is linked with a bacteria that lives in the stomach called Helicobacter pylori. But not everyone with Helicobacter pylori will develop stomach cancer. The most common symptoms of stomach cancer include: difficulty swallowing (dysphagia), weight loss, indigestion (dyspepsia) that doesn’t go away, feeling full after eating small amounts, feeling or being sick, and tiredness due to low red blood cells (anaemia). There are different types of treatment for patients with gastric cancer. Seven types of standard treatment are used: Surgery, Endoscopic mucosal resection, Chemotherapy, Radiation therapy, Chemoradiation, Targeted therapy, and Immunotherapy.

 

Request a sample and discover the recent advances in Gastric Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Gastric Cancer Treatment Landscape

 

Gastric Cancer Emerging Drugs 

 

IBI308: Innovent Biologics

IBI308 is a fully human monoclonal antibody that blocking programmed death protein-1. Innovent holds the global intellectual property rights of IBI308. Currently IBI308 has been approved for marketing by the NMPA. Acting as an immune checkpoint inhibitor by targeting PD-1, IBI308 boosts the immune response against tumor cells and inhibits the immune escape of tumor cells. Currently, it is in Phase III stage of clinical trial evaluation to treat gastric cancer.

 

HLX10: Henlix Biotech

It is a recombinant Humanised Anti-PD-1 Monoclonal Antibody Injection independently researched and developed by Henlius, is for the treatment of various solid tumors and can be applied in combination with other products for immuno-oncology therapy. Currently, it is in Phase III stage of clinical trial evaluation to treat gastric cancer.

 

Pamiparib: BeiGene

It is an investigational small molecule inhibitor of the PARP1 and PARP2 enzymes that is being evaluated as a potential monotherapy and in combination with other therapies to treat various solid tumors. Pamiparib’s early compound name was BGB-290. Currently, it is in Phase II stage of clinical trial evaluation to treat gastric cancer.

 

Gastric Cancer Pipeline Therapeutics Assessment

There are approx. 230+ key companies which are developing the therapies for Gastric Cancer. The companies which have their Gastric Cancer drug candidates in the most advanced stage, i.e. phase III include, Innovent Biologics.

 

For further information, refer to the detailed Gastric Cancer Unmet Needs, Gastric Cancer Market Drivers, and Gastric Cancer Market Barriers, click here @ CAR-T Ongoing Clinical Trial Analysis

 

Scope of the Gastric Cancer Pipeline Report

  • Coverage- Global
  • CompaniesMedipharma Limited, EMD Serono, Sumitomo Pharma, Jiangsu HengRui Medicine Co., Ltd., LintonPharm Co.,Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Eli Lilly and Company, Janssen Pharmaceutical K.K., Hoffmann-La Roche, Novartis, Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Merck Sharp & Dohme LLC, Amgen, Hanmi Pharmaceutical, and others.
  • Pipeline Therapies- Avelumab, BBI608, Camrelizumab, Catumaxomab, RAPA-201, SHR-1210, Amivantamab, Atezolizumab, Bevacizumab, Cabozantinib, Cinrebafusp alfa, Crizotinib, DKN-01, DP303c, Eflornithine, EP0057, Epacadostat, FLX475, Futibatinib, GEN-001, HLX07, HLX22, Infigratinib, KH903, Lenvatinib, Masitinib, MAX-40279, MRG002, MRG003, Niraparib, Savolitinib, Minnelide, SHR-1701, Margetuximab, Bemarituzumab, Evorpacept, Lenvatinib, CDK-004, TPX-0022,  TCRx_T Cells,  IN10018, IMU-131, SOT102, CT041, AB011, Zanidatamab, NC410,  PT 886, PRS-343, Oraxol, CA-4948,  Q702,  ACE1702, SI-B001, TT-4, LUM015,  LB 1908, CUE-102,  TORL-2-307-MAB,  OBI-833/OBI-821,  ASP2138, NC410, SO-C101, HC-5404-FU, CPL304110,  LNS8801, RGX-202-01, A166, GZ17-6.02, HMPL-453,  CCT303-406, VMD-928,  ITI 4000, PAb 001, and others.
  • Gastric Cancer Pipeline Segmentation: Phases, Molecule Type, Mechanism of Action, Route of Administration, Product Type

 

Table of Content

  1. Introduction
  2. Gastric Cancer Executive Summary
  3. Gastric Cancer: Overview
  4. Gastric Cancer Pipeline Therapeutics
  5. Gastric Cancer Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. IBI308: Innovent Biologics
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. Pamiparib: BeiGene
  11. Drug profiles in the detailed report…..
  12. Early Stage Products (Phase I)
  13. HC 5404 FU: HiberCell
  14. Drug profiles in the detailed report…..
  15. Preclinical and Discovery Stage Products
  16. PolyPEPI 1311: Treos Bio
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Gastric Cancer Key Companies
  20. Gastric Cancer Key Products
  21. Gastric Cancer- Unmet Needs
  22. Gastric Cancer- Market Drivers and Barriers
  23. Gastric Cancer- Future Perspectives and Conclusion
  24. Gastric Cancer Analyst Views
  25. Gastric Cancer Key Companies
  26. 26.   Appendix

 

Dive deep into rich insights for drugs for Gastric Cancer Market Drivers and Gastric Cancer Market Barriers, click here @ Gastric Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/anastomotic-leak-devices-market